Researchers report the development of a methodology to detect small amounts of potential tumor therapeutic targets, specificacally enzymes called kinases, that are present in biopsy samples. Therapies that directly inhibit cancer-promoting activities of some of these kinases have proven to be effective for patients in which individual driving kinases can be diagnosed.